TCR deal fren­zy con­tin­ues as blue­bird antes up $30M for new Grit­stone al­liance

Blue­bird bio $BLUE is jump­ing on the AI tar­get-iden­ti­fi­ca­tion plat­form de­vel­oped at the neo-anti­gen biotech Grit­stone to iden­ti­fy some new TCR pro­grams for the pipeline.

TCRs have been all the rage re­cent­ly as biotech fol­lows a tech trail that they be­lieve will lead to a wider range of can­cer drug tar­gets to go af­ter — par­tic­u­lar­ly in sol­id tu­mors, where cell ther­a­pies face some of their biggest chal­lenges. Just days ago blue­bird aligned on a T cell re­cep­tor de­vel­op­ment deal with biotech pow­er­house Re­gen­eron, bag­ging $100 mil­lion for a 50/50 pact on ac­cel­er­at­ing new pro­grams.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER